Analytical Data
-
Gene name
BGLF2
- Application
-
Species
Epstein-Barr virus
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0CK53
-
Expression Region
1-336aa
-
Molecular Weight
44.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BGLF2 is a pivotal protein encoded by the Epstein-Barr virus (EBV), a member of the herpesvirus family, which is known to establish lifelong latent infections in human hosts. The research on BGLF2 has gained interest due to its role in the viral lifecycle, specifically in the transition from latent to lytic phase. This protein is implicated in various cellular processes, including the regulation of host cell gene expression and the modulation of the immune response. Understanding BGLF2's structure and function is crucial for elucidating the mechanisms underlying EBV pathogenesis, including its involvement in lymphoproliferative disorders and other malignancies. Recent studies have focused on the potential of BGLF2 as a target for therapeutic interventions and vaccines, given its unique properties and expression patterns during viral reactivation. The investigation of BGLF2 typically involves recombinant protein expression and characterization techniques, enabling researchers to explore its interactions with host cellular factors and its effects on immune signaling pathways. Overall, BGLF2 represents a significant aspect of EBV research, with implications for both basic virology and the development of clinical strategies against EBV-associated diseases.
